Kitada, T., DiAndreth, B., Teague, B. & Weiss, R. Programming gene and engineered-cell therapies with synthetic biology. Science 359, eaad1067 (2018).
Xie, M. & Fussenegger, M. Designing cell function: assembly of synthetic gene circuits for cell biology applications. Nat. Rev. Mol. Cell Biol. 19, 507–525 (2018).
Cubillos-Ruiz, A. et al. Engineering living therapeutics with synthetic biology. Nat. Rev. Drug Discov. 20, 941–960 (2021).
Courbet, A., Endy, D., Renard, E., Molina, F. & Bonnet, J. Detection of pathological biomarkers in human clinical samples via amplifying genetic switches and logic gates. Sci. Transl. Med. 7, 289ra283 (2015).
Chang, H.-J. et al. Programmable receptors enable bacterial biosensors to detect pathological biomarkers in clinical samples. Nat. Commun. 12, 5216 (2021).
Kwong, G. A. et al. Synthetic biomarkers: a twenty-first century path to early cancer detection. Nat. Rev. Cancer 21, 655–668 (2021).
Danino, T. et al. Programmable probiotics for detection of cancer in urine. Sci. Transl. Med. 7, 289ra284–289ra284 (2015).
Panteli, J. T., Van Dessel, N. & Forbes, N. S. Detection of tumors with fluoromarker-releasing bacteria. Int. J. Cancer 146, 137–149 (2020).
Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426–1438.e1411 (2018).
Roybal, K. T. et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164, 770–779 (2016).
Fedorov, V. D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 5, 215ra172 (2013).
Kaseniit, K. E. et al. Modular, programmable RNA sensing using ADAR editing in living cells. Nat. Biotechnol. 41, 482–487 (2023).
Kawasaki, S., Fujita, Y., Nagaike, T., Tomita, K. & Saito, H. Synthetic mRNA devices that detect endogenous proteins and distinguish mammalian cells. Nucleic Acids Res. 45, e117–e117 (2017).
Wagner, T. E. et al. Small-molecule-based regulation of RNA-delivered circuits in mammalian cells. Nat. Chem. Biol. 14, 1043–1050 (2018).
Mc Cafferty, S. et al. In vivo validation of a reversible small molecule-based switch for synthetic self-amplifying mRNA regulation. Mol. Ther. 29, 1164–1173 (2021).
Vlahos, A. E. et al. Protease-controlled secretion and display of intercellular signals. Nat. Commun. 13, 912 (2022).
Wang, X. et al. A programmable protease-based protein secretion platform for therapeutic applications. Nat. Chem. Biol. 20, 432–442 (2023).
Gao, X. J., Chong, L. S., Kim, M. S. & Elowitz, M. B. Programmable protein circuits in living cells. Science 361, 1252–1258 (2018).
Chen, Z. et al. De novo design of protein logic gates. Science 368, 78 (2020).
Holt, B. A. & Kwong, G. A. Protease circuits for processing biological information. Nat. Commun. 11, 5021 (2020).
Holt, B. A. et al. Dimensionless parameter predicts bacterial prodrug success. Mol. Syst. Biol. 18, e10495 (2022).
Widen, J. C. et al. AND-gate contrast agents for enhanced fluorescence-guided surgery. Nat. Biomed. Eng. 5, 264–277 (2021).
Holt, B. A. et al. Embracing enzyme promiscuity with activity-based compressed biosensing. Cell Rep. Methods 3, 100372 (2023).
Zhuang, Q., Holt, B. A., Kwong, G. A. & Qiu, P. Deconvolving multiplexed protease signatures with substrate reduction and activity clustering. PLoS Comput. Biol. 15, e1006909 (2019).
Mac, Q. D. et al. Non-invasive early detection of acute transplant rejection via nanosensors of granzyme B activity. Nat. Biomed. Eng. 3, 281–291 (2019).
Mac, Q. D. et al. Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors. Nat. Biomed. Eng. 6, 310–324 (2022).
Werle, M. & Bernkop-Schnurch, A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30, 351–367 (2006).
Diao, L. & Meibohm, B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin. Pharmacokinet. 52, 855–868 (2013).
Jokerst, J. V., Lobovkina, T., Zare, R. N. & Gambhir, S. S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine 6, 715–728 (2011).
Kwong, G. A. et al. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat. Biotechnol. 31, 63–70 (2013).
Dall, E. & Brandstetter, H. Mechanistic and structural studies on legumain explain its zymogenicity, distinct activation pathways, and regulation. Proc. Natl Acad. Sci. USA 110, 10940–10945 (2013).
Aggarwal, S. et al. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry 47, 1076–1086 (2008).
Joo, S. H. Cyclic peptides as therapeutic agents and biochemical tools. Biomol. Ther. (Seoul) 20, 19–26 (2012).
Nielsen, D. S. et al. Orally absorbed cyclic peptides. Chem. Rev. 117, 8094–8128 (2017).
McKay, C. S. & Finn, M. G. Polyvalent catalysts operating on polyvalent substrates: a model for surface-controlled reactivity. Angew. Chem. Int. Ed. 55, 12643–12649 (2016).
Algar, W. R. et al. Proteolytic activity at quantum dot-conjugates: kinetic analysis reveals enhanced enzyme activity and localized interfacial “hopping”. Nano Lett. 12, 3793–3802 (2012).
Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827–837 (2016).
Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550–1558 (2018).
Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52–67 (2010).
Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309–5337 (2021).
Yap, T. A. et al. Development of immunotherapy combination strategies in cancer. Cancer Discov. 11, 1368–1397 (2021).
Nguyen, A. et al. Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy. Sci. Adv. 6, eabc2777 (2020).
Zhao, N. et al. In vivo measurement of granzyme proteolysis from activated immune cells with PET. ACS Cent. Sci. 7, 1638–1649 (2021).
Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25–39 (2020).
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
Smith, B. L. et al. Feasibility study of a novel protease-activated fluorescent imaging system for real-time, intraoperative detection of residual breast cancer in breast conserving surgery. Ann. Surg. Oncol. 27, 1854–1861 (2020).
Whitley, M. J. et al. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci. Transl. Med. 8, 320ra324 (2016).
Steinkamp, P. J. et al. A standardized framework for fluorescence-guided margin assessment for head and neck cancer using a tumor acidosis sensitive optical imaging agent. Mol. Imaging Biol. 23, 809–817 (2021).
Lord, S. J., Rajotte, R. V., Korbutt, G. S. & Bleackley, R. C. Granzyme B: a natural born killer. Immunol. Rev. 193, 31–38 (2003).
Trapani, J. A. & Sutton, V. R. Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr. Opin. Immunol. 15, 533–543 (2003).
Sun, Q. et al. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct. Target. Ther. 8, 320 (2023).
Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R. & Chandra, A. B. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) 12, 738 (2020).
Tune, B. X. J. et al. Matrix metalloproteinases in chemoresistance: regulatory roles, molecular interactions, and potential inhibitors. J. Oncol. 2022, 3249766 (2022).
Vyas, D., Laput, G. & Vyas, A. K. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. OncoTargets Ther. 7, 1015–1023 (2014).
Goodwin, R. A. & Asmis, T. R. Overview of systemic therapy for colorectal cancer. Clin. Colon Rectal Surg. 22, 251–256 (2009).
Zhang, X. et al. Hepatitis B virus reactivation in cancer patients with positive hepatitis B surface antigen undergoing PD-1 inhibition. J. Immunother. Cancer 7, 322 (2019).
Hutchinson, J. A. et al. Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. Nat. Commun. 12, 1439 (2021).
Esfahani, K. et al. Moving towards personalized treatments of immune-related adverse events. Nat. Rev. Clin. Oncol. 17, 504–515 (2020).
Kyi, C., Hellmann, M. D., Wolchok, J. D., Chapman, P. B. & Postow, M. A. Opportunistic infections in patients treated with immunotherapy for cancer. J. Immunother. Cancer 2, 19 (2014).
Del Castillo, M. et al. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin. Infect. Dis. 63, 1490–1493 (2016).
Zhu, I. et al. Modular design of synthetic receptors for programmed gene regulation in cell therapies. Cell 185, 1431–1443.e1416 (2022).
Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185–199 (2020).
Mo, F. et al. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat. Biotechnol. 39, 56–63 (2021).
Su, F.-Y. et al. In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles. Sci. Adv. 8, eabm7950 (2022).
Smith, T. T. et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 12, 813–820 (2017).
Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541–550 (2018).
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717–734 (2017).
He, S., Cheng, P. & Pu, K. Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine. Nat. Biomed. Eng. 7, 281–297 (2023).
Kratochwil, C. et al. (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J. Nucl. Med. 60, 801–805 (2019).
Galluzzi, L., Guilbaud, E., Schmidt, D., Kroemer, G. & Marincola, F. M. Targeting immunogenic cell stress and death for cancer therapy. Nat. Rev. Drug Discov. 23, 445–460 (2024).
Yatim, N., Cullen, S. & Albert, M. L. Dying cells actively regulate adaptive immune responses. Nat. Rev. Immunol. 17, 262–275 (2017).
Park, J.-H. et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv. Mater. 20, 1630–1635 (2008).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41565-024-01834-8